The short version of c-Met receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-08. Anything still debated is marked as such rather than presented as settled.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
The first flight of the US version, designated XP-51B took place in November 1942, but the USAAF had become so interested in the Merlin Mustang project that an initial contract for 400 aircraft was placed three months beforehand in August. The conversion led to production of the P-51B beginning at NAA's Inglewood, California, plant in June 1943, and P-51s started to become available to the 8th and 9th air forces in the winter of 1943–1944. Conversion to the two-stage supercharged and intercooled Merlin 60 series, over 350 lb (160 kg) heavier than the single-stage Allison, driving a four-bladed Hamilton Standard propeller, required moving the wing slightly forward to correct the aircraft's center of gravity. After the USAAF, in July 1943, directed fighter aircraft manufacturers to maximize internal fuel capacity, NAA calculated the P-51B's center of gravity to be forward enough to include an additional 85 US gal (320 L; 71 imp gal) fuel tank in the fuselage behind the pilot, greatly increasing the aircraft's range over that of the earlier P-51A. NAA incorporated the tank in the production of the P-51B-10, and supplied kits to retrofit it to all existing P-51Bs.
Fabrication and coating of nanodevices and medical implants to increase biocompatibility. Emulsifiers in food industry and personal care products. Hydrophobins' high stability can be very useful in the coating of surfaces of prolonged use or under harsh conditions. The easy dissociation of a class II hydrophobin monolayer might be desirable and this can easily be achieved by the use of detergents and alcohols. The use of hydrophobins in protein purification, drug delivery and cell attachment has been reported. For more about the potential biotechnological applications of hydrophobins see Hektor & Scholtmeijer (2005) and Cox & Hooley (2009).
== Non-insulin dependent (type 2) diabetes mellitus == The current releases of the downloadable AIDA software, and AIDA on-line, do not incorporate functions to model endogenous insulin secretion — which takes place in people with non-insulin dependent diabetes mellitus type 2, and healthy subjects without diabetes. Nevertheless, a wide number of people with insulin-treated type 2 diabetes mellitus have reported finding the AIDA diabetes simulator of use for learning about balancing insulin and diet in diabetes. This is because many of the principles of insulin dosage adjustment are remarkably similar in both type 1 and type 2 diabetes mellitus, and even without an endogenous insulin secretion model function, AIDA still can offer realistic simulations (from an educational perspective) for people with non-insulin dependent (type 2) diabetes mellitus. The AIDA developers have published a research paper in 2011 which includes reference to the incorporation of a dedicated function for pancreatic insulin secretion — to be added to a future release of the simulator.
Sources: en.wikipedia.org
=== Detection of sugar movement in plant tissue === In plant physiology, autoradiography can be used to determine sugar accumulation in leaf tissue. Sugar accumulation, as it relates to autoradiography, can described the phloem-loading strategy used in a plant. For example, if sugars accumulate in the minor veins of a leaf, it is expected that the leaves have few plasmodesmatal connections which is indicative of apoplastic movement, or an active phloem-loading strategy. Sugars, such as sucrose, fructose, or mannitol, are radiolabeled with [14-C], and then absorbed into leaf tissue by simple diffusion. The leaf tissue is then exposed to autoradiographic film (or emulsion) to produce an image. Images will show distinct vein patterns if sugar accumulation is concentrated in leaf veins (apoplastic movement), or images will show a static-like pattern if sugar accumulation is uniform throughout the leaf (symplastic movement).
By fascicle orientation Relative to the midline, rectus means parallel to the midline; transverse means perpendicular to the midline, and oblique means diagonal to the midline. Relative to the axis of the generation of force – types of parallel, and types of pennate muscles.
== Related diseases == In the metabolic disease combined malonic and methylmalonic aciduria (CMAMMA) due to ACSF3, a massive altered composition of complex lipids occurs as a result of impaired mitochondrial fatty acid synthesis (mtFAS). For example, while the concentration of sphingomyelin is noticeably increased, the concentration of ceramides is proportionally decreased.
Sources: en.wikipedia.org
The empire's inhabitants, today generally known as Byzantines, regarded themselves as Romans (in Greek, Ῥωμαῖοι or Romaioi). Similarly, their Islamic contemporaries called their empire the "land of the Romans" (Bilād al-Rūm). After 800 AD, Western Europe called them "Greeks" (Graeci), as the Papacy and medieval German emperors regarded themselves as the true inheritors of Roman identity. The adjective "Byzantine", derived from Byzantion (Byzantium in Latin), the name of the Greek settlement Constantinople was established on, was only used to describe the inhabitants of the city; it did not refer to the empire, called Rhomanía (Ῥωμανία or "Romanland") by its citizens. Following the empire's fall, early modern scholars referred to it by many names, including the "Eastern Empire", the "Low Empire", the "Late Empire", the "Empire of the Greeks", "Empire of Constantinople", and "Roman Empire". The increasing use of "Byzantine" and "Byzantine Empire" may have started with Theodore Metochites or Laonikos Chalkokondyles whose work was widely propagated by Hieronymus Wolf. "Byzantine" was used adjectivally alongside terms such as "Empire of the Greeks" until the 19th century. It is now the primary term, used to refer to all aspects of the empire; some modern historians believe it should not be used because it was originally a prejudicial and inaccurate term.
=== Taxonomy === In 1753, Linnaeus placed the tomato in the genus Solanum (alongside the potato) as Solanum lycopersicum. In 1768, Philip Miller moved it to its own genus, naming it Lycopersicon esculentum. The name came into wide use, but was technically in breach of the plant naming rules because Linnaeus's species name lycopersicum still had priority. Although the name Lycopersicum lycopersicum was suggested by Karsten (1888), it is not used because it violates the International Code of Nomenclature barring the use of tautonyms in botanical nomenclature. The corrected name Lycopersicon lycopersicum (Nicolson 1974) was technically valid, because Miller's genus name and Linnaeus's species name differ in exact spelling. As Lycopersicon esculentum has become so well known, it was officially listed as a nomen conservandum in 1983, and would be the correct name for the tomato in classifications which do not place the tomato in the genus Solanum. Genetic evidence shows that Linnaeus was correct to put the tomato in the genus Solanum, making S. lycopersicum the correct name. Both names, however, will probably be found in the literature for some time. Two of the major reasons for considering the genera separate are the leaf structure (tomato leaves are markedly different from any other Solanum), and the biochemistry (many of the alkaloids common to other Solanum species are conspicuously absent from the tomato).
Many birds actively defend a territory from others of the same species during the breeding season; maintenance of territories protects the food source for their chicks. Species that are unable to defend feeding territories, such as seabirds and swifts, often breed in colonies instead; this is thought to offer protection from predators. Colonial breeders defend small nesting sites, and competition between and within species for nesting sites can be intense. All birds lay amniotic eggs with hard shells made mostly of calcium carbonate. Hole and burrow nesting species tend to lay white or pale eggs, while open nesters lay camouflaged eggs. There are many exceptions to this pattern, however; the ground-nesting nightjars have pale eggs, and camouflage is instead provided by their plumage. Species that are victims of brood parasites have varying egg colours to improve the chances of spotting a parasite's egg, which forces female parasites to match their eggs to those of their hosts.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.